TP53 and neoplasm: Given this complexity of the TP53 alteration landscape and despite the remarkable depth of pre-clinical data characterizing the impact of diverse TP53 mutations on protein function6–8 it is not possible to interpret the anticipated function of TP53 mutations in patient tumors based on DNA mutation status alone, limiting the development of predictive or prognostic biomarkers and novel targeted therapy approaches based on this frequently mutated and crucial tumor suppressor.